Whitehawk Therapeutics (WHWK) CFO Scott M. Giacobello Receives Award

What Happened

• Scott M. Giacobello, CFO of Whitehawk Therapeutics (WHWK), received two derivative equity awards on September 15, 2026. Each grant was for 118,476 shares (totaling 236,952 shares) at $0.00 per share. These are awards/grants (derivative securities), not open-market purchases or sales.

Key Details

• Transaction date: 2026-09-15; reported on Form 4 filed 2026-09-15 (no late filing indicated).
• Awards: two grants of 118,476 shares each (derivative), total 236,952 shares; acquisition price reported as $0.00.
• Nature of awards: filing footnotes indicate one award is a restricted stock unit (RSU) (F2) and the awards are subject to vesting schedules (F1, F3).
• Vesting: Vesting Commencement Date = September 15, 2026. One award vests 25% after one year then 1/48th monthly thereafter to full vesting at year 4 (F1). The other vests 25% each year over four years (F3).
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• These are compensation grants (derivative/RSU-style awards) subject to multi-year vesting; they do not represent an immediate acquisition of tradable shares. They should be interpreted as standard equity compensation rather than an immediate bullish or bearish market signal.